Roche clears UK hurdle in $4.3 billion Spark deal, U.S. review drags on

ZURICH (Reuters) - Swiss drugmaker Roche won clearance from Britain's Competition and Markets Authority (CMA) on Monday for its planned $4.3 billion (3 billion pounds) takeover of gene therapy company Spark Therapeutics , while a similar U.S. review continues. Roche wants to buy U.S.-based Spark to gain a foothold in gene therapy as well as add to its portfolio against hemophilia A, where the Basel-based company already has the treatment Hemlibra that is due to surpass $1 billion sales this..